An overview of immune checkpoint inhibitors in breast cancer
Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors wi...
Ausführliche Beschreibung
Autor*in: |
Federica Miglietta [verfasserIn] Maria Silvia Cona [verfasserIn] Maria Vittoria Dieci [verfasserIn] Valentina Guarneri [verfasserIn] Nicla La Verde [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Exploration of Targeted Anti-tumor Therapy - Open Exploration Publishing Inc., 2021, 1(2020), 6, Seite 452-472 |
---|---|
Übergeordnetes Werk: |
volume:1 ; year:2020 ; number:6 ; pages:452-472 |
Links: |
---|
DOI / URN: |
10.37349/etat.2020.00029 |
---|
Katalog-ID: |
DOAJ061689416 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ061689416 | ||
003 | DE-627 | ||
005 | 20230309013237.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.37349/etat.2020.00029 |2 doi | |
035 | |a (DE-627)DOAJ061689416 | ||
035 | |a (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC31-1245 | |
100 | 0 | |a Federica Miglietta |e verfasserin |4 aut | |
245 | 1 | 3 | |a An overview of immune checkpoint inhibitors in breast cancer |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. | ||
650 | 4 | |a early breast cancer | |
650 | 4 | |a metastatic breast cancer | |
650 | 4 | |a immunotherapy | |
650 | 4 | |a immune checkpoint inhibitors | |
653 | 0 | |a Internal medicine | |
700 | 0 | |a Maria Silvia Cona |e verfasserin |4 aut | |
700 | 0 | |a Maria Vittoria Dieci |e verfasserin |4 aut | |
700 | 0 | |a Valentina Guarneri |e verfasserin |4 aut | |
700 | 0 | |a Nicla La Verde |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Exploration of Targeted Anti-tumor Therapy |d Open Exploration Publishing Inc., 2021 |g 1(2020), 6, Seite 452-472 |w (DE-627)174398264X |x 26923114 |7 nnns |
773 | 1 | 8 | |g volume:1 |g year:2020 |g number:6 |g pages:452-472 |
856 | 4 | 0 | |u https://doi.org/10.37349/etat.2020.00029 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 |z kostenfrei |
856 | 4 | 0 | |u https://www.explorationpub.com/Journals/etat/Article/100229 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2692-3114 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 1 |j 2020 |e 6 |h 452-472 |
author_variant |
f m fm m s c msc m v d mvd v g vg n l v nlv |
---|---|
matchkey_str |
article:26923114:2020----::nvriwfmuehcpitniios |
hierarchy_sort_str |
2020 |
callnumber-subject-code |
RC |
publishDate |
2020 |
allfields |
10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472 |
spelling |
10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472 |
allfields_unstemmed |
10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472 |
allfieldsGer |
10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472 |
allfieldsSound |
10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472 |
language |
English |
source |
In Exploration of Targeted Anti-tumor Therapy 1(2020), 6, Seite 452-472 volume:1 year:2020 number:6 pages:452-472 |
sourceStr |
In Exploration of Targeted Anti-tumor Therapy 1(2020), 6, Seite 452-472 volume:1 year:2020 number:6 pages:452-472 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine |
isfreeaccess_bool |
true |
container_title |
Exploration of Targeted Anti-tumor Therapy |
authorswithroles_txt_mv |
Federica Miglietta @@aut@@ Maria Silvia Cona @@aut@@ Maria Vittoria Dieci @@aut@@ Valentina Guarneri @@aut@@ Nicla La Verde @@aut@@ |
publishDateDaySort_date |
2020-01-01T00:00:00Z |
hierarchy_top_id |
174398264X |
id |
DOAJ061689416 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061689416</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309013237.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37349/etat.2020.00029</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061689416</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Federica Miglietta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="3"><subfield code="a">An overview of immune checkpoint inhibitors in breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">early breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastatic breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Silvia Cona</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Vittoria Dieci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicla La Verde</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Exploration of Targeted Anti-tumor Therapy</subfield><subfield code="d">Open Exploration Publishing Inc., 2021</subfield><subfield code="g">1(2020), 6, Seite 452-472</subfield><subfield code="w">(DE-627)174398264X</subfield><subfield code="x">26923114</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:452-472</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37349/etat.2020.00029</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.explorationpub.com/Journals/etat/Article/100229</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2692-3114</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield><subfield code="h">452-472</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Federica Miglietta |
spellingShingle |
Federica Miglietta misc RC31-1245 misc early breast cancer misc metastatic breast cancer misc immunotherapy misc immune checkpoint inhibitors misc Internal medicine An overview of immune checkpoint inhibitors in breast cancer |
authorStr |
Federica Miglietta |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)174398264X |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC31-1245 |
illustrated |
Not Illustrated |
issn |
26923114 |
topic_title |
RC31-1245 An overview of immune checkpoint inhibitors in breast cancer early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors |
topic |
misc RC31-1245 misc early breast cancer misc metastatic breast cancer misc immunotherapy misc immune checkpoint inhibitors misc Internal medicine |
topic_unstemmed |
misc RC31-1245 misc early breast cancer misc metastatic breast cancer misc immunotherapy misc immune checkpoint inhibitors misc Internal medicine |
topic_browse |
misc RC31-1245 misc early breast cancer misc metastatic breast cancer misc immunotherapy misc immune checkpoint inhibitors misc Internal medicine |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Exploration of Targeted Anti-tumor Therapy |
hierarchy_parent_id |
174398264X |
hierarchy_top_title |
Exploration of Targeted Anti-tumor Therapy |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)174398264X |
title |
An overview of immune checkpoint inhibitors in breast cancer |
ctrlnum |
(DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 |
title_full |
An overview of immune checkpoint inhibitors in breast cancer |
author_sort |
Federica Miglietta |
journal |
Exploration of Targeted Anti-tumor Therapy |
journalStr |
Exploration of Targeted Anti-tumor Therapy |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
txt |
container_start_page |
452 |
author_browse |
Federica Miglietta Maria Silvia Cona Maria Vittoria Dieci Valentina Guarneri Nicla La Verde |
container_volume |
1 |
class |
RC31-1245 |
format_se |
Elektronische Aufsätze |
author-letter |
Federica Miglietta |
doi_str_mv |
10.37349/etat.2020.00029 |
author2-role |
verfasserin |
title_sort |
overview of immune checkpoint inhibitors in breast cancer |
callnumber |
RC31-1245 |
title_auth |
An overview of immune checkpoint inhibitors in breast cancer |
abstract |
Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. |
abstractGer |
Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. |
abstract_unstemmed |
Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
6 |
title_short |
An overview of immune checkpoint inhibitors in breast cancer |
url |
https://doi.org/10.37349/etat.2020.00029 https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 https://www.explorationpub.com/Journals/etat/Article/100229 https://doaj.org/toc/2692-3114 |
remote_bool |
true |
author2 |
Maria Silvia Cona Maria Vittoria Dieci Valentina Guarneri Nicla La Verde |
author2Str |
Maria Silvia Cona Maria Vittoria Dieci Valentina Guarneri Nicla La Verde |
ppnlink |
174398264X |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.37349/etat.2020.00029 |
callnumber-a |
RC31-1245 |
up_date |
2024-07-03T22:10:43.839Z |
_version_ |
1803597532460220416 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061689416</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309013237.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37349/etat.2020.00029</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061689416</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Federica Miglietta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="3"><subfield code="a">An overview of immune checkpoint inhibitors in breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">early breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastatic breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Silvia Cona</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Vittoria Dieci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicla La Verde</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Exploration of Targeted Anti-tumor Therapy</subfield><subfield code="d">Open Exploration Publishing Inc., 2021</subfield><subfield code="g">1(2020), 6, Seite 452-472</subfield><subfield code="w">(DE-627)174398264X</subfield><subfield code="x">26923114</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:452-472</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37349/etat.2020.00029</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.explorationpub.com/Journals/etat/Article/100229</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2692-3114</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield><subfield code="h">452-472</subfield></datafield></record></collection>
|
score |
7.3998213 |